Biogen (BIIB) Stock Analysis & AI Equity Report
Biogen (BIIB) overview
Biogen (BIIB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 9,891m and operating profit of USD 1,862m; the year-end share price was 175.99 USD and market capitalisation was USD 25,835m. Biogen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biogen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Biogen
Biogen is a biopharmaceutical company that discovers, develops, and commercializes medicines for serious neurological, rare, and immunological diseases. Its portfolio includes therapies for multiple sclerosis, spinal muscular atrophy, Friedreich’s ataxia, ALS, geographic atrophy, paroxysmal nocturnal hemoglobinuria, and rare kidney diseases. Biogen completed its acquisition of Apellis Pharmaceuticals in May 2026, adding the FDA-approved medicines SYFOVRE and EMPAVELI.
Generate the Biogen report
Biogen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biogen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Biogen
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.